Eisai’s Leqembi makes debut alongside Lilly’s Kisunla in India, a market with close 9 million people living with dementia, but ecosystem gaps threaten early adoption. Pricing innovation could be pivotal to drive access.
Eisai’s Leqembi makes debut alongside Lilly’s Kisunla in India, a market with close 9 million people living with dementia, but ecosystem gaps threaten early adoption. Pricing innovation could be pivotal to drive access.